Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers

Rau,Kun-Ming; Huang,Chao-Cheng; Chiu,Tai-Jan; Chen,Yen-Yang; Lu,Chien-Chang; Liu,Chien-Ting; Pei,Sung-Nan; Wei,Yu-Ching

doi:10.3892/etm.2012.594

Neovascularization evaluated by CD105 correlates well with prognostic factors in breast cancers

Authors:
- Kun-Ming Rau
- Chao-Cheng Huang
- Tai-Jan Chiu
- Yen-Yang Chen
- Chien-Chang Lu
- Chien-Ting Liu
- Sung-Nan Pei
- Yu-Ching Wei
View Affiliations

Affiliations: Department of Internal Medicine, Division of Hematology-Oncology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, R.O.C. , Department of Anatomical Pathology, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, R.O.C. , Department of Colon and Rectal Surgery, Kaohsiung Chang Gung Memorial Hospital, Kaohsiung, Taiwan, R.O.C.
Published online on: May 30, 2012 https://doi.org/10.3892/etm.2012.594
Pages: 231-236

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Angiogenesis is critical for the growth, invasion and metastasis of cancers. Extensive neovascularization and tumor thrombus also correlate with a poor prognosis in breast cancer (BC). Although anti-angiogenic agents have been the therapies of choice for BC, in particular for triple-negative BCs, predictive markers for anti-angiogenic agents are lacking. Microvascular density (MVD) is commonly used to assess the neovascularization in tumors. Compared with pan-endothelial markers such as CD31, CD34 and von Willebrand factor (vWF), CD105 has a higher specificity for MVD in tumor tissues. In this study, we aimed to determine the prognostic value of CD105 in BCs. Paraffin‑embedded tissue blocks from 201 BC patients were formed into tissue microarrays. Evaluation of MVD revealed that a median of 11 microvessels determined by CD105 staining correlated significantly with the pathological characteristics of BCs and also with the survival of patients. The expression of CD105 correlated inversely with hormone receptor (HR) expression but positively with Her-2 expression. Univariate analysis indicated that CD105 is a superior predictor of disease‑free survival (DFS) in stage I and II diseases; multivariate analysis indicated that only hormone receptors (HRs) are suitable for predicting overall survival (OS) in stage III disease. These findings reveal for the first time that MVD measured by CD105 staining correlates positively with Her-2 expression but negatively with HR expression. The significance of MVD on OS is more apparent in early stage BCs. CD105 has the potential to be used as a predictive marker for anti-angiogenic agents; the targeting of CD105 may also be a potential anticancer strategy.

View Figures

View References

1.	Jemal A, Siegel R, Xu J and Ward E: Cancer statistics, 2010. CA Cancer J Clin. 60:277–300. 2010. View Article : Google Scholar
2.	Cianfrocca M and Gradishar W: New molecular classifications of breast cancer. CA Cancer J Clin. 59:303–313. 2009. View Article : Google Scholar
3.	Folkman J, Watson K, Ingber D and Hanahan D: Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature. 339:58–61. 1989. View Article : Google Scholar : PubMed/NCBI
4.	Gasparini G: Clinical significance of the determination of angiogenesis in human breast cancer: update of the biological background and overview of the Vicenza studies. Eur J Cancer. 32A:2485–2493. 1996. View Article : Google Scholar : PubMed/NCBI
5.	Uzzan B, Nicolas P, Cucherat M and Perret GY: Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res. 64:2941–2955. 2004. View Article : Google Scholar : PubMed/NCBI
6.	Nico B, Benagiano V, Mangieri D, Maruotti N, Vacca A and Ribatti D: Evaluation of microvascular density in tumors: pro and contra. Histol Histopathol. 23:601–607. 2008.PubMed/NCBI
7.	Fox SB, Gasparini G and Harris AL: Angiogenesis: pathological, prognostic, and growth-factor pathways and their link to trial design and anticancer drugs. Lancet Oncol. 2:278–289. 2001. View Article : Google Scholar : PubMed/NCBI
8.	Woodfin A, Voisin MB and Nourshargh S: PECAM-1: a multi-functional molecule in inflammation and vascular biology. Arterioscler Thromb Vasc Biol. 27:2514–2523. 2007. View Article : Google Scholar : PubMed/NCBI
9.	Mineo TC, Ambrogi V, Baldi A, et al: Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumour vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol. 57:591–597. 2004. View Article : Google Scholar : PubMed/NCBI
10.	da Silva BB, Lopes-Costa PV, dos Santos AR, et al: Comparison of three vascular endothelial markers in the evaluation of microvessel density in breast cancer. Eur J Gynaecol Oncol. 30:285–288. 2009.PubMed/NCBI
11.	Tanaka F, Otake Y, Yanagihara K, et al: Evaluation of angio-genesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res. 7:3410–3415. 2001.PubMed/NCBI
12.	Fonsatti E, Del Vecchio L, Altomonte M, et al: Endoglin: an accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol. 188:1–7. 2001. View Article : Google Scholar : PubMed/NCBI
13.	Kumar S, Ghellal A, Li C, et al: Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res. 59:856–861. 1999.PubMed/NCBI
14.	Dallas NA, Samuel S, Xia L, et al: Endoglin (CD105): a marker of tumor vasculature and potential target for therapy. Clin Cancer Res. 14:1931–1937. 2008. View Article : Google Scholar : PubMed/NCBI
15.	Yao Y, Kubota T, Takeuchi H and Sato K: Prognostic significance of microvessel density determined by an anti-CD105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. Neuropathology. 25:201–206. 2005. View Article : Google Scholar : PubMed/NCBI
16.	Elliott RL and Blobe GC: Role of transforming growth factor beta in human cancer. J Clin Oncol. 23:2078–2093. 2005. View Article : Google Scholar : PubMed/NCBI
17.	Yamamoto T, Kozawa O, Tanabe K, et al: Involvement of p38 MAP kinase in TGF-beta-stimulated VEGF synthesis in aortic smooth muscle cells. J Cell Biochem. 82:591–598. 2001. View Article : Google Scholar : PubMed/NCBI
18.	Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C and Kumar S: CD105 antagonizes the inhibitory signaling of transforming growth factor beta1 on human vascular endothelial cells. FASEB J. 14:55–64. 2000.PubMed/NCBI
19.	Seon BK, Haba A, Matsuno F, et al: Endoglin-targeted cancer therapy. Curr Drug Deliv. 8:135–143. 2011. View Article : Google Scholar : PubMed/NCBI
20.	Marinho A, Soares R, Ferro J, Lacerda M and Schmitt FC: Angiogenesis in breast cancer is related to age but not to other prognostic parameters. Pathol Res Pract. 193:267–273. 1997. View Article : Google Scholar : PubMed/NCBI
21.	Sørlie T, Perou CM, Tibshirani R, et al: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 98:10869–10874. 2001.PubMed/NCBI
22.	Liedtke C and Kiesel L: Current issues of targeted therapy in metastatic triple-negative breast cancer. Breast Care (Basel). 6:234–239. 2011. View Article : Google Scholar : PubMed/NCBI
23.	Niers TM, Richel DJ, Meijers JC and Schlingemann RO: Vascular endothelial growth factor in the circulation in cancer patients may not be a relevant biomarker. PLoS One. 6:e198732011. View Article : Google Scholar : PubMed/NCBI
24.	Pang R and Poon RT: Angiogenesis and antiangiogenic therapy in hepatocellular carcinoma. Cancer Lett. 242:151–167. 2006. View Article : Google Scholar : PubMed/NCBI
25.	Webber K, Cooper A, Kleiven H, Yip D and Goldstein D: Management of metastatic renal cell carcinoma in the era of targeted therapies. Intern Med J. 41:594–605. 2011. View Article : Google Scholar : PubMed/NCBI
26.	Kesisis G, Kontovinis LF, Gennatas K and Kortsaris AH: Biological markers in breast cancer prognosis and treatment. J BUON. 15:447–454. 2010.PubMed/NCBI
27.	Klos KS, Wyszomierski SL, Sun M, et al: ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res. 66:2028–2037. 2006. View Article : Google Scholar
28.	Hanahan D and Weinberg RA: Hallmarks of cancer: the next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI
29.	Chien CY, Su CY, Hwang CF, et al: Clinicopathologic significance of CD105 expression in squamous cell carcinoma of the hypopharynx. Head Neck. 28:441–446. 2006. View Article : Google Scholar : PubMed/NCBI
30.	Dales JP, Garcia S, Andrac L, et al: Prognostic significance of angiogenesis evaluated by CD105 expression compared to CD31 in 905 breast carcinomas: Correlation with long-term patient outcome. Int J Oncol. 24:1197–1204. 2004.
31.	Rau KM, Kang HY, Cha TL, Miller SA and Hung MC: The mechanisms and managements of hormone-therapy resistance in breast and prostate cancers. Endocr Relat Cancer. 12:511–532. 2005. View Article : Google Scholar : PubMed/NCBI
32.	Davoli A, Hocevar BA and Brown TL: Progression and treatment of HER2-positive breast cancer. Cancer Chemother Pharmacol. 65:611–623. 2010. View Article : Google Scholar : PubMed/NCBI
33.	Roy V and Perez EA: Beyond trastuzumab: small molecule tyrosine kinase inhibitors in HER-2-positive breast cancer. Oncologist. 14:1061–1069. 2009. View Article : Google Scholar : PubMed/NCBI
34.	Nam JS, Terabe M, Mamura M, et al: An anti-transforming growth factor beta antibody suppresses metastasis via cooperative effects on multiple cell compartments. Cancer Res. 68:3835–3843. 2007. View Article : Google Scholar : PubMed/NCBI
35.	She X, Matsuno F, Harada N, Tsai H and Seon BK: Synergy between anti-endoglin (CD105) monoclonal antibodies and TGF-beta in suppression of growth of human endothelial cells. Int J Cancer. 108:251–257. 2004. View Article : Google Scholar : PubMed/NCBI
36.	Uneda S, Toi H, Tsujie T, et al: Anti-endoglin monoclonal antibodies are effective for suppressing metastasis and the primary tumors by targeting tumor vasculature. Int J Cancer. 125:1446–1453. 2009. View Article : Google Scholar : PubMed/NCBI
37.	Lee SH, Mizutani N, Mizutani M, et al: Endoglin (CD105) is a target for an oral DNA vaccine against breast cancer. Cancer Immunol Immunother. 55:1565–1574. 2006. View Article : Google Scholar : PubMed/NCBI
38.	Wood LM, Pan ZK, Guirnalda P, Tsai P, Seavey M and Paterson Y: Targeting tumor vasculature with novel Listeria-based vaccines directed against CD105. Cancer Immunol Immunother. 60:931–942. 2011. View Article : Google Scholar
39.	Foy KC, Liu Z, Phillips G, Miller M and Kaumaya PT: Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumor and anti-angiogenic responses in vitro and in vivo. J Biol Chem. 286:13626–13637. 2011. View Article : Google Scholar : PubMed/NCBI